Cover Image
市場調查報告書

胃輕癱:開發平台分析

Gastroparesis - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 213078
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
胃輕癱:開發平台分析 Gastroparesis - Pipeline Review, H2 2015
出版日期: 2015年09月09日 內容資訊: 英文 40 Pages
簡介

所謂胃輕癱是指慢性的胃臟無法正常消化食物的狀態。 症狀有食慾衰退、體重減輕、膨脹感、腹痛和不舒服、噁心和嘔吐等。原因有糖尿病、帕金森氏症、硬皮症、類澱粉沉積症等。

本報告提供胃輕癱的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊,再加上最新的新聞和發表等資訊。

簡介

  • 調查範圍

胃輕癱 概要

治療藥的開發

  • 開發中產品概要
  • 開發中產品比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的開發企業

  • GlaxoSmithKline plc
  • RaQualia Pharma Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • camicinal
  • ETX-101
  • NG-101
  • RQ-00000010
  • RQ-00201894
  • velusetrag

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7150IDB

Summary

Global Markets Direct's, 'Gastroparesis - Pipeline Review, H2 2015', provides an overview of the Gastroparesis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroparesis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Gastroparesis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Gastroparesis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Gastroparesis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Gastroparesis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Gastroparesis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Gastroparesis Overview
  • Therapeutics Development
    • Pipeline Products for Gastroparesis - Overview
    • Pipeline Products for Gastroparesis - Comparative Analysis
  • Gastroparesis - Therapeutics under Development by Companies
  • Gastroparesis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Gastroparesis - Products under Development by Companies
  • Gastroparesis - Companies Involved in Therapeutics Development
    • GlaxoSmithKline Plc
    • RaQualia Pharma Inc.
  • Gastroparesis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • camicinal - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ETX-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ETX-301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NG-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00000010 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00201894 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • velusetrag hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Gastroparesis - Recent Pipeline Updates
  • Gastroparesis - Dormant Projects
  • Gastroparesis - Product Development Milestones
    • Featured News & Press Releases
      • May 18, 2015: Theravance Biopharma Presents Positive Phase 2 Study Data on Velusetrag (TD-5108) for Treatment of Gastroparesis in "Poster of Distinction" at Digestive Disease Week (DDW) 2015
      • Mar 12, 2015: Theravance Biopharma Announces Initiation of Phase 2b Study of Velusetrag (TD-5108) for the Treatment of Gastroparesis
      • Jan 07, 2014: RaQualia Receives a Patent Allowance for Motilin Receptor Agonist in the USA
      • Jan 08, 2013: Theravance And Alfa Wassermann Announce Initiation Of Phase II Study With Velusetrag For Gastroparesis
      • Sep 14, 2012: RaQualia Pharma's Motilin Receptor Agonist RQ-00201894 Advances To Pre-clinical Stage
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Gastroparesis, H2 2015
  • Number of Products under Development for Gastroparesis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Gastroparesis - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Gastroparesis - Pipeline by RaQualia Pharma Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Gastroparesis Therapeutics - Recent Pipeline Updates, H2 2015
  • Gastroparesis - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Gastroparesis, H2 2015
  • Number of Products under Development for Gastroparesis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top